Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia.

Michelson AP, McDonough S, Willman CL, Koegle ER, Godwin JE, Petersdorf SH, List AF, Othus M, Appelbaum FR, Radich JP, Ganapathi MK, Advani AS, Ganapathi RN.

Sci Rep. 2020 Mar 26;10(1):5486. doi: 10.1038/s41598-020-62345-9.

2.

RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.

Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN.

Cancers (Basel). 2020 Mar 7;12(3). pii: E620. doi: 10.3390/cancers12030620.

3.

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Norris EJ, Zhang Q, Jones WD, DeStephanis D, Sutker AP, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.

J Pathol. 2019 Jul;248(3):352-362. doi: 10.1002/path.5264. Epub 2019 May 14.

4.

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.

Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.

Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15.

5.

Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.

Norris EJ, Jones WD, Surleac MD, Petrescu AJ, Destephanis D, Zhang Q, Hamadeh I, Kneisl JS, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol Rep. 2018 Jan 17;23:41-44. doi: 10.1016/j.gore.2018.01.005. eCollection 2018 Feb.

6.

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.

Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022.

PMID:
29402501
7.

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.

Kozuki T, Chikamori K, Surleac MD, Micluta MA, Petrescu AJ, Norris EJ, Elson P, Hoeltge GA, Grabowski DR, Porter ACG, Ganapathi RN, Ganapathi MK.

Nucleic Acids Res. 2017 Jun 2;45(10):5995-6010. doi: 10.1093/nar/gkx325.

8.

Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer.

Miller KR, Patel JN, Ganapathi MK, Tait DL, Ganapathi RN.

Gynecol Oncol. 2016 Jun;141(3):608-615. doi: 10.1016/j.ygyno.2016.03.004. Epub 2016 Mar 21. Review.

PMID:
26957480
9.

Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.

Ganapathi MK, Jones WD, Sehouli J, Michener CM, Braicu IE, Norris EJ, Biscotti CV, Vaziri SA, Ganapathi RN.

Int J Cancer. 2016 Feb 1;138(3):679-88. doi: 10.1002/ijc.29815. Epub 2015 Sep 10.

10.

Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs.

Ganapathi RN, Ganapathi MK.

Urol Oncol. 2014 Jan;32(1):1-4. doi: 10.1016/j.urolonc.2013.08.027. No abstract available.

PMID:
24360658
11.

Mechanisms regulating resistance to inhibitors of topoisomerase II.

Ganapathi RN, Ganapathi MK.

Front Pharmacol. 2013 Aug 1;4:89. doi: 10.3389/fphar.2013.00089. eCollection 2013.

12.

Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.

Vaziri SA, Tavares EJ, Golshayan AR, Rini BI, Aydin H, Zhou M, Sercia L, Wood L, Ganapathi MK, Bukowski RM, Ganapathi R.

Front Oncol. 2012 May 28;2:51. doi: 10.3389/fonc.2012.00051. eCollection 2012.

13.

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi R.

Cancer. 2012 Apr 1;118(7):1946-54. doi: 10.1002/cncr.26491. Epub 2011 Aug 31.

14.

Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Grozav AG, Willard BB, Kozuki T, Chikamori K, Micluta MA, Petrescu AJ, Kinter M, Ganapathi R, Ganapathi MK.

Proteomics. 2011 Mar;11(5):829-42. doi: 10.1002/pmic.201000194. Epub 2011 Jan 31.

15.

CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.

Fader AN, Rasool N, Vaziri SA, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, Rojas-Espaillat L, Belinson JL, Ganapathi MK, Ganapathi R.

Anticancer Res. 2010 Dec;30(12):4791-8.

PMID:
21187454
16.

DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.

Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK.

Curr Cancer Drug Targets. 2010 Nov;10(7):758-71. Review.

PMID:
20578986
17.

Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors.

Vaziri SA, Kim J, Ganapathi MK, Ganapathi R.

Curr Oncol Rep. 2010 Mar;12(2):102-8. doi: 10.1007/s11912-010-0085-4. Review.

PMID:
20425594
18.

Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.

Vaziri SA, Grabowski DR, Hill J, Rybicki LR, Burk R, Bukowski RM, Ganapathi MK, Ganapathi R.

Anticancer Res. 2009 Aug;29(8):2961-9.

19.

Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.

Grozav AG, Chikamori K, Kozuki T, Grabowski DR, Bukowski RM, Willard B, Kinter M, Andersen AH, Ganapathi R, Ganapathi MK.

Nucleic Acids Res. 2009 Feb;37(2):382-92. doi: 10.1093/nar/gkn934. Epub 2008 Nov 29.

20.

Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.

Chikamori K, Hill JE, Grabowski DR, Zarkhin E, Grozav AG, Vaziri SA, Wang J, Gudkov AV, Rybicki LR, Bukowski RM, Yen A, Tanimoto M, Ganapathi MK, Ganapathi R.

Leukemia. 2006 Oct;20(10):1809-18. Epub 2006 Aug 17.

PMID:
16932348
21.

Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.

Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T.

Anticancer Res. 2006 May-Jun;26(3A):1869-76.

22.

Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.

Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK, Ganapathi R.

Mol Cancer Ther. 2005 Dec;4(12):1880-90.

23.

c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.

Vaziri SA, Grabowski DR, Tabata M, Holmes KA, Sterk J, Takigawa N, Bukowski RM, Ganapathi MK, Ganapathi R.

Anticancer Res. 2003 Sep-Oct;23(5A):3657-61.

PMID:
14666661
24.

Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.

Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, Aebersold RH, Bukowski RM, Hickson ID, Andersen AH, Ganapathi R, Ganapathi MK.

J Biol Chem. 2003 Apr 11;278(15):12696-702. Epub 2003 Feb 4.

25.

Telomerase activity in stage II colorectal carcinoma.

Kawanishi-Tabata R, Lopez F, Fratantonio S, Kim N, Goldblum J, Tubbs R, Elson P, Lavery I, Bukowski RM, Ganapathi R, Ganapathi MK.

Cancer. 2002 Nov 1;95(9):1834-9.

26.

Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.

Ganapathi R, Vaziri SA, Tabata M, Takigawa N, Grabowski DR, Bukowski RM, Ganapathi MK.

Curr Pharm Des. 2002;8(22):1945-58. Review.

PMID:
12171521
27.

Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependent enzymes.

Aoyama M, Grabowski DR, Holmes KA, Rybicki LA, Bukowski RM, Ganapathi MK, Ganapathi R.

Biochem Pharmacol. 2001 Jan 1;61(1):49-54.

PMID:
11137708
28.

Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.

Tabata M, Tabata R, Grabowski DR, Bukowski RM, Ganapathi MK, Ganapathi R.

J Biol Chem. 2001 Mar 16;276(11):8029-36. Epub 2000 Dec 13.

29.

Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.

Grabowski DR, Holmes KA, Aoyama M, Ye Y, Rybicki LA, Bukowski RM, Ganapathi MK, Hickson ID, Ganapathi R.

Mol Pharmacol. 1999 Dec;56(6):1340-5.

PMID:
10570063
30.
31.

Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.

Aoyama M, Grabowski DR, Isaacs RJ, Krivacic KA, Rybicki LA, Bukowski RM, Ganapathi MK, Hickson ID, Ganapathi R.

Blood. 1998 Oct 15;92(8):2863-70.

PMID:
9763571
32.

Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells.

Aoyama M, MacIsaac D, Bukowski RM, Ganapathi MK.

Clin Cancer Res. 1998 Apr;4(4):1039-45.

33.

Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.

Ganapathi MK, Weizer AK, Borsellino S, Bukowski RM, Ganapathi R, Rice T, Casey G, Kawamura K.

Cell Growth Differ. 1996 Jul;7(7):923-9.

35.

Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells.

Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I.

J Immunol. 1991 Aug 15;147(4):1261-5.

PMID:
1651357
36.

Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines.

Mackiewicz A, Speroff T, Ganapathi MK, Kushner I.

J Immunol. 1991 May 1;146(9):3032-7.

PMID:
1707930
37.

Induction of C-reactive protein by cytokines in human hepatoma cell lines is potentiated by caffeine.

Ganapathi MK, Mackiewicz A, Samols D, Brabenec A, Kushner I, Schultz D, Hu SI.

Biochem J. 1990 Jul 1;269(1):41-6.

38.

Transforming growth factor beta 1 regulates production of acute-phase proteins.

Mackiewicz A, Ganapathi MK, Schultz D, Brabenec A, Weinstein J, Kelley MF, Kushner I.

Proc Natl Acad Sci U S A. 1990 Feb;87(4):1491-5.

39.

Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines.

Ganapathi MK, May LT, Schultz D, Brabenec A, Weinstein J, Sehgal PB, Kushner I.

Biochem Biophys Res Commun. 1988 Nov 30;157(1):271-7. No abstract available.

PMID:
2461709
40.

Regulation of rabbit acute phase protein biosynthesis by monokines.

Mackiewicz A, Ganapathi MK, Schultz D, Samols D, Reese J, Kushner I.

Biochem J. 1988 Aug 1;253(3):851-7.

41.

Heterogeneous nature of the acute phase response. Differential regulation of human serum amyloid A, C-reactive protein, and other acute phase proteins by cytokines in Hep 3B cells.

Ganapathi MK, Schultz D, Mackiewicz A, Samols D, Hu SI, Brabenec A, Macintyre SS, Kushner I.

J Immunol. 1988 Jul 15;141(2):564-9.

PMID:
2454996
42.

Cloning and cDNA sequence of the dihydrolipoamide dehydrogenase component human alpha-ketoacid dehydrogenase complexes.

Pons G, Raefsky-Estrin C, Carothers DJ, Pepin RA, Javed AA, Jesse BW, Ganapathi MK, Samols D, Patel MS.

Proc Natl Acad Sci U S A. 1988 Mar;85(5):1422-6.

43.

Cloning of rat brain succinyl-CoA:3-oxoacid CoA-transferase cDNA. Regulation of the mRNA in different rat tissues and during brain development.

Ganapathi MK, Kwon M, Haney PM, McTiernan C, Javed AA, Pepin RA, Samols D, Patel MS.

Biochem J. 1987 Dec 15;248(3):853-7.

44.

Monokines regulate glycosylation of acute-phase proteins.

Mackiewicz A, Ganapathi MK, Schultz D, Kushner I.

J Exp Med. 1987 Jul 1;166(1):253-8.

45.

Induction of succinyl-coenzyme A:3-oxoacid coenzyme A-transferase during differentiation of 3T3-L1 cells.

Ganapathi MK, Raefsky C, Patel MS.

Arch Biochem Biophys. 1986 Jan;244(1):114-21.

PMID:
2418783
46.
47.

Isolation and characterization of a high molecular weight protein phosphatase from rabbit skeletal muscle.

Paris H, Ganapathi MK, Silberman SR, Aylward JH, Lee EY.

J Biol Chem. 1984 Jun 25;259(12):7510-8.

48.

Isolation and characterization of rabbit skeletal muscle protein phosphatases C-I and C-II.

Silberman SR, Speth M, Nemani R, Ganapathi MK, Dombradi V, Paris H, Lee EY.

J Biol Chem. 1984 Mar 10;259(5):2913-22.

50.

The phosphoprotein phosphatases: properties of the enzymes involved in the regulation of glycogen metabolism.

Lee EY, Silberman SR, Ganapathi MK, Petrović S, Paris H.

Adv Cyclic Nucleotide Res. 1980;13:95-131. Review. No abstract available.

PMID:
6251707

Supplemental Content

Loading ...
Support Center